<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817126</url>
  </required_header>
  <id_info>
    <org_study_id>REAL</org_study_id>
    <nct_id>NCT02817126</nct_id>
  </id_info>
  <brief_title>Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer</brief_title>
  <acronym>REAL</acronym>
  <official_title>Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer (REAL): A Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and oncological feasibility of&#xD;
      robot-assisted surgery for mid/low rectal carcinoma compared with laparoscopic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic surgery as the treatment for colon cancer has been widely recognized. But its&#xD;
      use for rectal cancer is still controversial. Previous trials have shown that although the&#xD;
      long-term survival outcomes were similar, laparoscopic surgery did not reach the&#xD;
      non-inferiority in terms of local tumor radical resection, compared with open surgery.&#xD;
      Robotic techniques are considered to improve the quality of surgery with three-dimensional&#xD;
      vision, stable camera platform and flexible robotic arms. Meta-analyses have shown that&#xD;
      compared with laparoscopic surgery, robotic surgery could improve surgical quality in terms&#xD;
      of open conversion, circumferential resection margin, postoperative complications,&#xD;
      postoperative recovery, and quality of life, with similar long-term survival. However, these&#xD;
      evidences mainly came from retrospective studies and small-scale randomized controlled trials&#xD;
      with low quality. There still needs high-quality clinical trials to confirm the advantages of&#xD;
      robotic surgery for rectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 10, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional recurrence rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>The proportion of patients with any cancer recurrence in the pelvic or perineal area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circumferential resection margin positive rate</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>The proportion of patients with circumferential resection margin ≤ 1 mm from the tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication rate</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>The proportion of patients with any complications occurred within 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Time from surgery to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival time</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Time from surgery to any recurrence, metastases or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Day 1</time_frame>
    <description>Time from making skin incision to suturing the incision during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of conversion to open surgery</measure>
    <time_frame>Day 1</time_frame>
    <description>The proportion of patients with the use of a laparotomy incision for any part of the TME procedure or lymph nodes dissection during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood loss will be measured according to the suction and the weight of wet gauze, and then minus the irrigation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proximal/distal resection margin</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>The proximal/distal resection margin will be reported as &quot;positive&quot; or &quot;negative&quot; to define whether tumor is radically resected. It will be reported according to the post-operative pathology. Details are based on NCCN and Chinese guidelines for colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of retrieved lymph nodes</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>The number of lymph node found from the surgical specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>The postoperative hospital stay is defined as the number of date from the first day after operation to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported bladder function</measure>
    <time_frame>At postoperative 3, 6 and 12 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;International prostate symptom score&quot; (IPSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported sexual function for male patients</measure>
    <time_frame>At postoperative 3, 6 and 12 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;International Index of Erectile Function&quot; (IIEF-5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported sexual function for female patients</measure>
    <time_frame>At postoperative 3, 6 and 12 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;Female Sexual Function Index&quot; (FSFI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1240</enrollment>
  <condition>Rectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Robot-assisted surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo robot-assisted resections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo laparoscopic resections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robot-assisted resection</intervention_name>
    <description>Arm I: Robot-assisted resection using da vinci system.</description>
    <arm_group_label>Robot-assisted surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic resection</intervention_name>
    <description>Arm II: Traditional laparoscopic resection.</description>
    <arm_group_label>Laparoscopic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) class I - III;&#xD;
&#xD;
          -  Histologically proved rectal adenocarcinoma;&#xD;
&#xD;
          -  Inferior tumor edge ≤ 12 cm from anal verge, measured by rigid rectoscopy;&#xD;
&#xD;
          -  Tumor assessed as cT1-T3 (mesorectal fascia not involved) N0-1, or ycT1-T3 Nx after&#xD;
             preoperative radio- or chemoradiotherapy, measured by pelvic MRI;&#xD;
&#xD;
          -  No evidence of distant metastases;&#xD;
&#xD;
          -  No other malignancies in medical history except adequately treated basocellular&#xD;
             carcinoma of the skin or in situ carcinoma of the cervix uteri;&#xD;
&#xD;
          -  Suitable for both robotic and laparoscopic surgery;&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors assessed as clinical complete response after preoperative radio- or&#xD;
             chemoradiotherapy;&#xD;
&#xD;
          -  Tumors assessed as cT1N0 and suitable for local excision;&#xD;
&#xD;
          -  Signs of acute intestinal obstruction, bleeding or perforation needing emergency&#xD;
             surgery;&#xD;
&#xD;
          -  Multiple colorectal tumors or other schedules needing for synchronous colon surgery;&#xD;
&#xD;
          -  Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.);&#xD;
&#xD;
          -  Co-existent inflammatory bowel disease;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Patients received treatment other than preoperative radio- or chemoradiotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Xu, Ph.D., M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100141</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Southwest Hospital of Army Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>671014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital of Northern Theatre Command (former Shenyang Military General Hospital)</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>123005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 960th Hospital of Chinese PLA Joint Logistic Support Force (former Jinan Military General Hospital)</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Naval Medical University (Changhai Hospital)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Head of Colorectal Surgery</investigator_title>
  </responsible_party>
  <keyword>Minimally Invasive Surgical Procedures</keyword>
  <keyword>Robotic Surgical Procedures</keyword>
  <keyword>Laparoscopic Surgical Procedures</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Intraoperative Complications</keyword>
  <keyword>Postoperative Complications</keyword>
  <keyword>Recovery of Function</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Disease Progression</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

